Email ID : 
Password : 
Forgot Your Password ? 

Only Report Titles
Titles & Keywords
NOTE: Site best viewed with Internet Explorer
  INTRANASAL DRUG DELIVERY
A US Market Report

This report analyzes the US market for Intranasal Drug Delivery in US$ Million. The product is analyzed by the following Therapeutic Areas: Allergic Infections, Analgesics, Osteoporosis, and Vaccinations. Annual forecasts are provided for the period of 2000 through 2015. The report profiles 77 companies including many key and niche players such as Aegis Therapeutics LLC, Alza Corporation, AptarGroup, Inc., Archimedes Pharma Limited, AstraZeneca Plc, MedImmune, Inc., Bayer Consumer Care, Bespak Plc, GlaxoSmithKline Plc, Intranasal Therapeutics, Inc., Javelin Pharmaceuticals, Inc., Kurve Technology, Inc., Nastech Pharmaceutical Company, Inc., Novartis AG, OptiNose AS, Pfizer, Inc., Rexam Plc, Schering-Plough Corporation, Sanofi-Aventis S.A., and Unigene Laboratories, Inc. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

CODE:    MCP-1795  PAGES:    214
PRICE:    $3950  DATE:       May 2008
COMPANIES:  77  MARKET DATA TABLES:   31
Due to the proprietary nature, our previews are offered only to manufacturers, top-tier management consultants, investment banks, and investment research groups.

 TABLE OF CONTENTS  
  INTRANASAL DRUG DELIVERY (Complete Report) Pages : 214   | $3950
I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS3$100
   Study Reliability and Reporting Limitations.....I-1  
   Disclaimers.....I-2
Data Interpretation & Reporting Level.....I-2
Quantitative Techniques & Analytics.....I-2
  
   Product Definitions and Scope of Study.....I-3  
II. A US MARKET REPORT62$3000
  1. Industry Overview.....II-18 $550  
   Drug Delivery: A Quick Primer.....II-1
The Nose: An Attractive Avenue to Cross the Blood Brain Barrier.....II-1
1$75
   Self-Administration of Drugs Brings Intranasal Drug Delivery Into the
  Spotlight.....II-2
Research & Technology Opens Up New Therapeutic Areas for Nasal Drug Delivery.....II-2
Recent Product Developments in the US Intranasal Drug Delivery Market (2007).....II-2
1$75
   Table 1: The US Nasal Drug Delivery Market: Sales Of Top Six Nasal Formulations for The Year 2005 (In US$ Million) (includes corresponding Graph/Chart).....II-3
R&D: Critical to the Commercialization of Intranasal Drug Delivery.....II-3
Tight Junction Biology: A Key Speed Breaker in Commercialization.....II-3
1$150
   RNA Interference (RNAi): A Tool To Manipulate Tight Junctions.....II-4
Why Is Nasal Drug Delivery the Theme of All Drug Delivery Research Projects?.....II-4
Nasal Drug Delivery Devices & Equipments.....II-4
Preservative Free Systems (P.F.S.).....II-4
2$150
   Traditional Vs Advanced Intranasal Drug Delivery Devices.....II-6
Pitfalls Of Traditional Delivery Devices.....II-6
The Promise of New Advanced Delivery Devices.....II-6
Bi-Directional Nasal Drug Delivery: A Technology With a Huge Potential.....II-6
1$75
   Benefits of Bi-Directional Delivery Authenticated Through Research Studies.....II-7
Market for Nasal Spray Devices in the US.....II-7
1$75
   GSK Wields the Leadership Scepter in the US Intranasal Drugs Market.....II-8
The Batting Order.....II-8
Table 2: US Market for Intranasal Drug Delivery (2004-2006): Percentage Market Share Breakdown of Leading Players - GlaxoSmithKline, Schering-Plough, AstraZeneca, Sanofi-Aventis, and Others (includes corresponding Graph/Chart).....II-8
1$150
  2. Market Dynamics.....II-94 $300  
   Innovation in Drug Delivery: A Talisman For Success.....II-9
Controlled Release Technology Is the Buzz Word.....II-9
Target-Specific Delivery Devices: Of Critical Value.....II-9
Safety and Cost: Primary Growth Drivers.....II-9
1$75
   Preservatives Losing Sheen in Nasal Spray Formulations.....II-10
Multi-Dose Containers Evolve to Offer Resistance Against Microbial
  Contamination.....II-10
Bioavailability: An Important Facet of Intranasal Drug Delivery.....II-10
Chemical Modification.....II-10
1$75
   Transient Modification & Limited Enzymatic Activity.....II-11
Bioavailability of Large Molecules.....II-11
Bio-Adhesive Polymers: Useful in Increasing Drug Absorption.....II-11
Mixed Opinions on Efficiency of Calcitonin Nasal Spray.....II-11
Nasal Preparations Gaining Foothold in Cough and Allergic Categories.....II-11
1$75
   Patent Expiries Impact Market Opportunities.....II-12
1$75
  3. Technology Overview.....II-139 $675  
   Intranasal Drug Delivery: A Descriptive Exposition.....II-13
Nasal Physiology.....II-13
1$75
   Challenges Involved In Formulating Nasal Drugs.....II-141$75
   The Importance of Bioadhesion.....II-15
Challenges Involved In Designing Devices.....II-15
Overview on the Traditional Drug Administration Routes, Molecular Weight
  Capabilities, and Dosage Range.....II-15
1$75
   Intranasal Drugs - Prescription (Rx) and Over-the- Counter (OTC).....II-16
Differences Between Systemic Delivery and Local Effects.....II-16
Nasal Powders Vs Sprays.....II-16
1$75
   Nasal Drug Delivery Devices.....II-17
Types of Drug Delivery Devices.....II-17
Droppers.....II-17
Sprays.....II-17
Aerosol Containers/Inhalers.....II-17
1$75
   Pumps.....II-18
Nasal Aspirator.....II-18
Intranasal Drug Delivery Vis-à-vis Other Delivery Techniques.....II-18
Table 3: US Market for Intranasal Drugs: Percentage share of Topical and Systemic Drugs by value for the Years 2006 and 2012.....II-18
1$150
   Limitations of Intranasal Drug Delivery.....II-19
Allergy.....II-19
Definition.....II-19
Symptoms.....II-19
1$75
   Allergic Rhinitis.....II-20
Nasal Allergies.....II-20
Table 4: US Market for Nasal Sprays, Drops and Inhalers: Top 10 Brands Ranked by Dollar Sales Through Drug Stores for the Year Ended January 2008 (In US $ Million) (includes corresponding Graph/Chart).....II-20
1$150
   Table 5: US Market for Nasal Sprays, Drops and Inhalers: Top 10 Brands Ranked by Unit Sales Through Drug Stores for the Year Ended January 2008 (In Thousand Units) (includes corresponding Graph/Chart).....II-21

Table 6: US Market for Nasal Sprays: Top Five Nasal Sprays for Cough, Cold, Sinus and Allergy Ranked by Dollar Retail Sales for the Year Ended January 2008 (In US $ Million) (includes corresponding Graph/Chart).....II-21
1$150
  4. Nasal Drugs: An Overview.....II-229 $575  
   Nasal Drugs For Allergies.....II-22
Corticosteroid Nasal Sprays.....II-22
Flonase.....II-22
Patanase.....II-22
Beconase.....II-22
1$75
   Other Nasal Corticosteroid Drugs.....II-23
Antihistamine Nasal Sprays.....II-23
Astelin Nasal Spray.....II-23
Otrivin Nasal Spray.....II-23
Livostin Nasal Spray.....II-23
Other Nasal Antihistamine Drugs.....II-23
1$75
   Other Brands of Allergy Relievers.....II-24
Nasal Drugs for Postmenopausal Osteoporosis.....II-24
Calcitonin–Salmon Nasal Spray.....II-24
Miacalcin Nasal Spray.....II-24
Fortical® Nasal Spray.....II-24
Intranasal Pain Management Drugs.....II-24
1$75
   Stadol Nasal Spray.....II-25
Rylomine.....II-25
Imitrex.....II-25
1$75
   Migranal.....II-26
Zolmitriptan Nasal Spray.....II-26
Intranasal Analgesics For Treating Migraine.....II-26
Select Intranasal Pain Management Products in Development.....II-26
1$75
   Intranasal Vaccination.....II-27
Process of Intranasal Immunization.....II-27
1$75
   Market Drivers.....II-28
“LAIV” Nasal Spray Flu Vaccine.....II-28
FluMist® Vaccine From MedImmune.....II-28
1$75
   Intranasal Drugs for Sexual Dysfunction.....II-29
Table 7: US Market for Intranasal Drugs: Projected Revenues for Intranasal Sexual Dysfunction Drugs for the Years 2010 through 2012 in US$ Million (includes corresponding Graph/Chart).....II-29
1$150
   Nasal Spray for Treating Vitamin B12 Deficiency.....II-30
Nasal Spray for Aiding Smoking Cessation.....II-30
Intranasal Drugs In the Pipeline.....II-30
1$75
  5. Research & Development.....II-318 $600  
   Nastech Enrolls 551 Patients for Phase 2 Trials of PYY3-36 Nasal Spray.....II-31
Archimedes Pharma Commences Phase III Trials for NasalFent®.....II-31
Archimedes Presents New Clinical Data on NasalFent®.....II-31
LigoCyte Commences Clinical Trials for Intranasal Norovirus Vaccine.....II-31
Javelin Pharmaceuticals Reveals Phase 2 Study Results for PMI-100/150.....II-31
1$75
   Javelin Pharmaceuticals Commences Phase III Studies for PMI-150.....II-32
Nastech Commences Phase 2 Trials for Insulin Nasal Spray.....II-32
ACAAI Reveals Results for Trials of Nasacort® AQ Nasal Spray in Children.....II-32
1$75
   TGAR01H from Fabre Kramer.....II-33
Aegis Therapeutics Completes First Human Clinical Study on Intravail®.....II-33
Nastech Pharmaceutical Presents Clinical Test Results on Parathyroid Hormone.....II-33
Zolmitriptan Promises Relief for Cluster Headaches.....II-33
1$75
   CAIV-T: More Effective than Injectable Influenza Vaccines.....II-34
Intranasal Therapeutics Conducts Study on Midazolam.....II-34
Nastech Announces Phase I Results of Insulin Nasal Spray.....II-34
1$75
   Archimedes Completes Phase II Trials of NASALFENT.....II-35
Intranasal Corticosteroid Proven Effective for Treating Allergic Rhinitis.....II-35
Aegis Files DMF for Intravail.....II-35
Nasal Sprays: A New-Generation Treatment for Gynecological Problems.....II-35
1$75
   Aegis Therapeutics Conducts Feasibility Study on Drug Delivery Technology.....II-36
GelVac Powder Delivery System Completes Phase I Clinical Trial.....II-36
1$75
   DelSite Files DMF with the FDA.....II-37
OptiNose Develops Intranasal Delivery System for Osteoporosis.....II-37
Nastech Initiates Dose Ranging Study of PYY(3-36).....II-37
Valois Develops New Nasal Dispensing System.....II-37
1$75
   Rigel Pharmaceuticals to Initiate R112 Phase II Clinical Trial.....II-38
MedPointe Pharmaceuticals Demonstrates ACT1 Study Results on ASTELIN®.....II-38
Bentley Pharmaceuticals Demonstrates Clinical Trial Results of its Intra Nasal Insulin
  Spray.....II-38
1$75
  6. Recent Technological Developments.....II-392 $150  
   New-Generation Technologies and Devices.....II-39
ViaNase from Kurve Technology.....II-39
A New Product from OptiNose.....II-39
1$75
   Nastech’s “Tight Junction Biology” Research Program.....II-40
ChiSys™ Nasal Delivery Technology from Archimedes.....II-40
1$75
  7. Product Innovations/Introductions.....II-413 $225  
   Aegis Therapeutics Develops ProTek™.....II-41
Heel Launches Luffeel® in the US.....II-41
Palatin Technologies to Develop Bremelanotide.....II-41
Archimedes to Introduce Intranasal Formulation of Human Growth Hormone.....II-41
Sinofresh Launches SinoFresh™ Nasal & Sinus Care.....II-41
1$75
   PARI Respiratory Launches Nasal Drug Delivery Program.....II-42
OptiNose to Develop New Range of Intranasal Products.....II-42
OptiNose and Cambridge Consultants to Develop Advanced Nasal Delivery Device.....II-42
Kurve Technology Develops ViaNase ID™.....II-42
1$75
   Upsher-Smith Introduces Fortical® Nasal Spray.....II-43
Schering-Plough Launches New Formulation of NASONEX®.....II-43
AstraZeneca Unveils Rhinocort Aqua in the US.....II-43
1$75
  8. Recent Industry Activity.....II-4411 $825  
   Zelos Therapeutics Collaborates with Aegis Therapeutics.....II-44
ImmuneRegen BioSciences Partners with LRRI.....II-44
Avamys™ Nasal Spray Receives Approval in Europe.....II-44
PMI-150 Receives Canadian Patent.....II-44
1$75
   USFDA Approves FluMist® for Young Children.....II-45
USFDA Approves Veramyst Nasal Spray for Individuals Aged Two Years and Above.....II-45
Kurve Technology Inks Agreement with Schering-Plough.....II-45
MedImmune Clarifies FDA Observations.....II-45
FluMist(R) Receives FDA Approval for Refrigerated Formulation.....II-45
Nastech Regains Rights for PTH1-34 Nasal Spray.....II-45
1$75
   NASONEX(R) Receives Ease-of-Use Commendation from Arthritis Foundation.....II-46
Aegis Therapeutics Establishes Cedar Therapeutics Inc......II-46
EMEA Provides Encouraging Feedback for Avamys™ Nasal Spray.....II-46
Kurve Technologies Introduces Blog on Nasal Drug Delivery.....II-46
Accentia Extends Agreement with Mayo Foundation.....II-46
1$75
   Nastech Signs Development and License Agreement with Amylin.....II-47
MedImmune's FluMist Plant Gets FDA Approval.....II-47
ShinNippon Subsidiaries Sign Licensing Agreement with Tokai Pharmaceuticals.....II-47
MeadWestvaco Acquires Saint-Gobain Calmar.....II-47
Merck Terminates PYY3-36 Partnership with Nastech.....II-47
1$75
   Inspire Signs Licensing Agreement with Boehringer Ingelheim.....II-48
P&G Partners with Nastech to Develop PTH(1-34).....II-48
1$75
   Unigene Laboratories Signs Distribution Agreement with Tzamal Bio Pharma.....II-49
GlaxoSmithKline Seeks Marketing Approval for Fluticasone Furoate in the US and
  Europe.....II-49
Kurve Technology Relocates Corporate Headquarters.....II-49
Kurve Inks an Agreement with DARA BioSciences.....II-49
Kurve Enters into a Development Agreement with Schering-Plough.....II-49
Altana Submits NDS for Approval of Ciclesonide Nasal Spray in Canada.....II-49
1$75
   Altana Pharma AG Receives FDA Approval for Pediatric Use of Omnaris.....II-50
Intranasal Therapeutics Inc. Receives Financial Funding.....II-50
FDA Completes Pre-Approval Inspections at Nastech’s Washington Facility.....II-50
Kos Signs Exclusive License Agreement with SkyePharma.....II-50
Bentley Signs Agreement with Biocon.....II-50
1$75
   MedImmune Files New Drug Application with the FDA.....II-51
Intranasal Therapeutics Files Patent Application for Synthetic THC.....II-51
Ionix Pharmaceuticals in Collaboration with Reckitt Benckiser for Drug
  Development.....II-51
University of Kentucky Receives Patent for new Intranasal Device.....II-51
1$75
   Intranasal Technology Extends Collaboration with Aegis Therapeutics.....II-52
Accentia Biopharmaceuticals Signs License Agreement with Collegium
  Pharmaceuticals.....II-52
Aegis Therapeutics Extends License Agreement with Intranasal Technologies.....II-52
Bentley Pharmaceuticals Signs Agreement with Dong Sung Pharmaceuticals.....II-52
1$75
   Unigene Gets FDA Approval for Fortical Calcitonin- Salmon Nasal Spray.....II-53
OptiNose Signs Collaborative Agreement with MedPharm.....II-53
West Pharmaceutical Divests Drug Delivery Business to Archimedes Pharma.....II-53
Nastech Pharmaceutical Receives FDA Approval for Nascobal Nasal Spray.....II-53
Par and Nastech Sign Licensing Agreement.....II-53
1$75
   Aegis Therapeutics Signs Licensing Agreement with University of Alabama.....II-54
ITI Receives a Patent for Sedation Inducing Nasal Drug.....II-54
Inyx Bags Order from Australian OTC Drug Company.....II-54
1$75
  9. Focus on Select Global Players.....II-556 $450  
   Aegis Therapeutics LLC (USA).....II-55
Alza Corporation (USA).....II-55
AptarGroup, Inc. (USA).....II-55
1$75
   Archimedes Pharma Limited. (UK).....II-56
AstraZeneca Plc (UK).....II-56
MedImmune, Inc. (USA).....II-56
1$75
   Bayer Consumer Care (USA).....II-57
Bespak Plc (UK).....II-57
GlaxoSmithKline Plc (UK).....II-57
1$75
   Intranasal Therapeutics, Inc. (USA).....II-58
Javelin Pharmaceuticals, Inc (USA).....II-58
Kurve Technology, Inc. (USA).....II-58
Nastech Pharmaceutical Company, Inc. (USA).....II-58
1$75
   Novartis AG (Switzerland).....II-59
OptiNose AS (Norway).....II-59
Pfizer, Inc. (USA).....II-59
1$75
   Rexam Plc (UK).....II-60
Schering-Plough Corporation (USA).....II-60
Sanofi-Aventis S.A. (France).....II-60
Unigene Laboratories, Inc. (USA).....II-60
1$75
  10. Market Analytics.....II-612 $300  
   Table 8: US Recent Past, Current & Future Analysis for Intranasal Drug Delivery by Therapeutic Area – Allergic Infections, Analgesics, Osteoporosis, and Vaccinations Markets Independently Analyzed by Annual Sales Figures in US$ Million for Years 2000 through 2010.....II-61

Table 9: US Long-term Projections for Intranasal Drug Delivery by Therapeutic Area – Allergic Infections, Analgesics, Osteoporosis, and Vaccinations Markets Independently Analyzed by Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....II-61
1$150
   Table 10: US 10-Year Perspective for Intranasal Drug Delivery by Therapeutic Area –Percentage Breakdown of Values Sales for Allergic Infections, Analgesics, Osteoporosis, and Vaccinations for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart).....II-621$150
III. COMPETITIVE LANDSCAPE 143$995
  
Total Companies Profiled: 77 (including Divisions/Subsidiaries - 92)

Region/Country                 Players

The United States                 54
Canada                             2
Japan                              3
Europe                            28 
     France                        4
     Germany                       6
     The United Kingdom           13
     Rest of Europe                5 
Asia-Pacific (Excluding Japan)     2
Middle East                        3
Click here to request a full table of contents and more details on this project.		  
 
 
Due to the proprietary nature, our previews are offered only to manufacturers, top-tier management consultants, investment banks, and investment research groups.

© Copyrights 2010, Global Industry Analysts, Inc., USA.